NCT00353561

Diabetes Mellitus and Vulvovaginal Candidiasis

Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Indian Council of Medical Research · Other Government
• Sex: Female
• Age: 18 Years – 66 Years
• Healthy volunteers: Not accepted

Summary

Clinical and mycological response to oral fluconazole and boric acid suppositories was assessed in patients with diabetes mellitus and vulvovaginal candidiasis.

Detailed description

A high proportion of vulvovaginal candidiasis is due to C.glabrata that responds poorly to fluconazole therapy. We assessed the clinical relief and mycological cure in response to oral fluconazole and boric acid suppositories in patients with diabetes mellitus and vulvovaginal candidiasis given in a Randomized trial. Fluconazole was given in standard oral single dose (150 mg) fluconazole and boric acid vaginal suppositories was given in dose of 600 mg/daily for 14 uninterrupted days.

Conditions

• Diabetes Mellitus
• Vulvovaginal Candidiasis

Interventions

Type	Name	Description
DRUG	Boric	Gelatin capsules filled with 600 mg of boric acid
DRUG	Fluconazole	150 mg oral fluconazole gives once in 14 days

Timeline

• Start date: 2004-06-01
• Primary completion: 2006-04-01
• Completion: 2006-04-01
• First posted: 2006-07-18
• Last updated: 2008-05-22

Locations

1 site across 1 country: India